Navigation Links
Research: Improving treatment of patients with heart attack
Date:6/25/2009

This release is available in French.

Montreal, June 25th 2009 When faced with patients suffering a heart attack, doctors have two choices: inject them with medication to dissolve the blood clot (fibrinolytic therapy) or insert a small balloon to open the blocked artery (primary percutaneous coronary intervention (PCI)). Guidelines for treating heart attacks are generally based on clinical trials that do not take "real-life" conditions into account. The latest study by Dr. Thao Huynh of the Research Institute of the MUHC analyses these gaps and provides potential solutions to improve treatment of heart attack. Her article was published in the June 23rd issue of Circulation.

In this study, Dr. Huynh compares the results of 23 randomized controlled trials conducted under controlled experimental conditions, with the results of 32 observational studies reporting on the treatment of patients with heart attacks in routine clinical conditions.

Both types of studies show the superiority of PCI over fibrinolytic therapy in reducing mortality and the risk of further episodes of cardiac arrest and stroke over the short term. However, the advantage of PCI is even more apparent in randomized controlled trials where delays in providing primary PCI are shorter than in routine clinical conditions.

"This study indeed demonstrates that we have to work to reduce these delays if we are to maximize the effectiveness of PCI," explained Dr. Huynh. "When it comes to treating heart attack, reducing delays in providing treatment is the number one priority. It is also essential that patients with symptoms of heart attack seek prompt medical attention. Delays by patients to seek medical attention may further increase delays to treatment of heart attack. "

Analysis of randomized controlled trials shows that primary PCI also reduces long-term mortality and repeat heart attack. However, this long-term benefit of primary PCI is not observed in observational studies where patients receive treatment within routine clinical conditions.

"The benefit of primary PCI can be lost over the long term if patients are not receiving optimal medical therapy after discharge from hospital. These medications are essential to prevent repeat heart attack." warned Dr. Huynh.


'/>"/>

Contact: Isabelle Kling
isabelle.klign@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Manhattan Research: Physician New Media Adoption in Emerging Pharma Markets - Webcast April 3
2. Radiological Society of North America research: Cancer risk from cardiac CT overstated
3. New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest
4. Conning Research: Long Term Care Insurance Industry Continues to Search for Broader Market
5. New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows
6. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
7. Manhattan Research: ePharma Consumer(R) Research and Advisory Service Now Available
8. Broad Coalition Says Consumer Role Is Key to Improving Health and Health Care
9. Beth Israel Medical Center Receives Major American Cancer Society Grant Toward Improving Pain Management in Chinese Cancer Patients
10. United Spinal Associations 2009 Independence Expo Aug. 7th-8th In Orlando: Improving Life for the Disabled and the Aging
11. United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the leader ... the position of Executive Vice President, Sales and Marketing. Finnegan is a widely ... medical device sales leadership. He has received industry recognition for innovations and new ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 ... survey data released today by the American Society for Dermatologic Surgery ... the percentage of consumers considering a cosmetic medical procedure has doubled since 2013. ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a DAO (decentralized autonomous ... Ethereum blockchain, has released their technical specifications . , 2017 has seen an ... systematic approach for determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder ...
(Date:6/27/2017)... Orlando, FL (PRWEB) , ... June 27, 2017 ... ... the leading payment solution for many of the health care industry’s hospitals and ... its new patient financing portal for select customers. Parasail Health is a San ...
Breaking Medicine News(10 mins):
(Date:6/27/2017)... AVIV, Israel , June 27, 2017  Therapix ... specialty clinical-stage pharmaceutical company specializing in the development of ... The Nasdaq Stock Market Opening Bell in ... 2017 in honor of its initial public offering (IPO) ... Capital Market in March 2017. Dr. Elran ...
(Date:6/27/2017)... 27, 2017   NuEyes (NuEyes Technologies Inc.) today ... fuel its growth in helping the legally blind live more ... Group), the leading developer of augmented, virtual and mixed reality ... The undisclosed funding amount was provided by strategic partners ... with offices in Abu Dhabi , ...
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, 2017 ... that validate the use of MMprofiler with SKY92, the ... myeloma (MM). In a poster presentation at the 22 ... in Madrid, Spain , SkylineDx researchers ... high-risk elderly patients. In a separate ...
Breaking Medicine Technology: